InMed Pharmaceuticals Inc(INM),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

INM InMed Pharmaceuticals Inc

Post-Mkt 03-17 18:51:18 EDT

0.8900

+0.0284

+3.30%

盘后0.8900

+0.00000.00%

16:04 EDT

High0.9260	Low0.8200	Vol120.20K
Open0.8696	D1 Closing0.8616	Amplitude12.30%
Mkt Cap2.60M	Tradable Cap1.32M	Total Shares2.92M
T/O106.65K	T/O Rate8.10%	Tradable Shares1.48M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"INM","market":"US","secType":"STK","nameCN":"InMed Pharmaceuticals Inc","latestPrice":0.89,"timestamp":1773777600000,"preClose":0.8616,"halted":0,"volume":120195,"hourTrading":{"tag":"盘后","latestPrice":0.89,"preClose":0.89,"latestTime":"16:04 EDT","volume":126,"amount":116.58000059999999,"timestamp":1773777852213,"change":0,"changeRate":0,"amplitude":0.049888},"delay":0,"changeRate":0.032961931290622075,"floatShares":1484000,"shares":2919186,"eps":-2.88,"marketStatus":"Post-Mkt","change":0.0284,"latestTime":"03-17 18:51:18 EDT","open":0.8696,"high":0.926,"low":0.82,"amount":106650.955053,"amplitude":0.123027,"askPrice":0.91,"askSize":200,"bidPrice":0.8,"bidSize":10,"shortable":3,"etf":0,"ttmEps":-2.88,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1773792000000},"marketStatusCode":4,"adr":0,"exchange":"NASDAQ","adjPreClose":0.8616,"preHourTrading":{"tag":"盘前","latestPrice":0.8299,"preClose":0.8616,"latestTime":"09:16 EDT","volume":2432,"amount":2028.04560256,"timestamp":1773753397295,"change":-0.0317,"changeRate":-0.036792,"amplitude":0.104341},"postHourTrading":{"tag":"盘后","latestPrice":0.89,"preClose":0.89,"latestTime":"16:04 EDT","volume":126,"amount":116.58000059999999,"timestamp":1773777852213,"change":0,"changeRate":0,"amplitude":0.049888},"volumeRatio":2.739862},"requestUrl":"/m/hq/s/INM/tweets","defaultTab":"tweets","newsList":[{"id":"2618625365","title":"InMed Pharmaceuticals provides development outlook for 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2618625365","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618625365?lang=en_us&edition=fundamental","pubTime":"2026-03-09 20:01","pubTimestamp":1773057691,"startTime":"0","endTime":"0","summary":"InMed Pharmaceuticals (INM) provides a pharmaceutical development outlook for 2026. 2026 Development Priorities for INM-901 include: Conduct a pre-...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/inmed-pharmaceuticals-provides-development-outlook-for-2026-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/inmed-pharmaceuticals-provides-development-outlook-for-2026-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","INM"],"gpt_icon":0},{"id":"2618790628","title":"InMed targets 2027 Phase 1 trial start for INM-901 and plans FDA pre-IND meeting in Q3 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2618790628","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618790628?lang=en_us&edition=fundamental","pubTime":"2026-03-09 19:31","pubTimestamp":1773055919,"startTime":"0","endTime":"0","summary":"InMed said it is preparing for a pre-IND meeting with the FDA in Q3 2026 for its INM-901 Alzheimer’s program and is targeting an IND submission and Phase 1 trial start in 2027. In preclinical studies, INM-901 significantly reduced inflammatory biomarkers including IFN-γ and TNF-α in a 5xFAD mouse model. In an LPS-induced neuroinflammation model, INM-901 significantly reduced inflammasome activation and pro-inflammatory markers including NLRP3 and IL-6. InMed also said it plans a pre-IND meeting with the FDA in Q4 2026 for INM-089 in dry age-related macular degeneration.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260309:nNDL7sR1XF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INM","BK4007"],"gpt_icon":0},{"id":"2617665318","title":"InMed winds down BayMedica commercial operations to focus on drug development pipeline","url":"https://stock-news.laohu8.com/highlight/detail?id=2617665318","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617665318?lang=en_us&edition=fundamental","pubTime":"2026-03-07 06:06","pubTimestamp":1772834768,"startTime":"0","endTime":"0","summary":"InMed Pharmaceuticals Inc. said its board has approved BayMedica LLC’s plan to wind down and exit its commercial operations, citing uncertainty around proposed U.S. federal legislation that could restrict parts of BayMedica’s cannabinoid business and inventory. The company expects the wind-down to be substantially completed before BayMedica’s fiscal year-end on June 30, 2026, while continuing limited sales, marketing, manufacturing, and logistics during the transition. InMed said it will then focus exclusively on advancing its drug development pipeline, including INM-901 for Alzheimer’s disease and INM-089 for dry age-related macular degeneration, and expects to incur about $550,000 in severance costs plus roughly $120,000 in additional related expenditures through fiscal 2026.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260306:nNDL4FBMts:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","INM"],"gpt_icon":0},{"id":"2617653921","title":"BRIEF-InMed Pharmaceuticals Inc - On March 4, Co Confirmed And Approved The Decision To Wind Down Baymedica's Commercial Operations - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2617653921","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617653921?lang=en_us&edition=fundamental","pubTime":"2026-03-07 06:02","pubTimestamp":1772834579,"startTime":"0","endTime":"0","summary":"BRIEF-InMed Pharmaceuticals Inc - On March 4, Co Confirmed And Approved The Decision To Wind Down Baymedica's Commercial Operations - SEC FilingMarch 6  - InMed Pharmaceuticals Inc INM.O:INMED PHARMACEUTICALS INC - ON MARCH 4, CO CONFIRMED AND APPROVED THE DECISION TO WIND DOWN BAYMEDICA'S COMMERCIAL OPERATIONS - SEC FILINGINMED PHARMACEUTICALS INC - BAYMEDICA TO COMPLETE WIND DOWN BEFORE FISCAL YEAR ENDING JUNE 30, 2026 - SEC FILINGFurther company coverage: INM.O ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260306:nFWN3ZU0UJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INM","BK4007"],"gpt_icon":0},{"id":"2617653549","title":"InMed Pharmaceuticals Inc - on March 4, Co Confirmed and Approved the Decision to Wind Down Baymedica's Commercial Operations - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2617653549","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617653549?lang=en_us&edition=fundamental","pubTime":"2026-03-07 05:59","pubTimestamp":1772834369,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260306:nFWN3ZU0UJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["INM","BK4007"],"gpt_icon":0},{"id":"2617653800","title":"InMed pro forma net loss widens 18% to $8.83 million for FY2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2617653800","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617653800?lang=en_us&edition=fundamental","pubTime":"2026-03-07 05:58","pubTimestamp":1772834334,"startTime":"0","endTime":"0","summary":"InMed Pharmaceuticals reported a net loss of $3.76 million for the six months ended Dec. 31, 2025. On a pro forma basis assuming BayMedica’s commercial operations were treated as discontinued, the company posted a net loss of $3.76 million, including a $0.02 million loss from discontinued operations. Pro forma operating loss from continuing operations was $3.91 million, and interest and other income was $0.17 million. InMed ended Dec. 31, 2025 with $6.95 million in cash and cash equivalents and $11.19 million in total assets. On a pro forma basis, cash and cash equivalents were $6.74 million and total liabilities were $2.27 million.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. InMed Pharmaceuticals Inc. published the original content","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260306:nNDL2QLQp0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INM","BK4007"],"gpt_icon":0},{"id":"2610706942","title":"InMed Pharmaceuticals Inc. Q2 BayMedica revenue drops 26% to USD 0.8 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2610706942","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610706942?lang=en_us&edition=fundamental","pubTime":"2026-02-12 19:04","pubTimestamp":1770894246,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. InMed Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on February 12, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260212:nNDLYYmmc:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INM","BK4007"],"gpt_icon":0},{"id":"2610910964","title":"InMed Pharma Q4 R&D expenses USD 0.63 million, down 30%","url":"https://stock-news.laohu8.com/highlight/detail?id=2610910964","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610910964?lang=en_us&edition=fundamental","pubTime":"2026-02-12 06:05","pubTimestamp":1770847513,"startTime":"0","endTime":"0","summary":"InMed Pharmaceuticals Inc. reported its results for the quarter ended December 31, 2025. For the Pharma segment, research and development expenses were USD 0.63 million for the quarter, marking a 30 percentage point decrease. General and administrative expenses totaled USD 1.32 million, a decrease of 3 percentage points. Amortization and depreciation expenses were USD 0.05 million, reflecting a 2 percentage point decrease. During the period, InMed advanced its INM-901 program, completing the first preclinical study with the oral formulation administered in large animals. These results will guide the design of a planned human Phase 1 clinical trial. The company also completed additional chemistry, manufacturing, and controls development to scale up the INM-901 manufacturing process in preparation for Investigational New Drug enabling studies and regulatory interactions with the FDA. Revenue for the company is derived from manufacturing and distribution sales of bulk rare cannabinoid pro","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260211:nNDL8hWlBQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INM","BK4007"],"gpt_icon":0},{"id":"2592947515","title":"InMed Pharmaceuticals Inc. Held Annual Shareholder Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2592947515","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592947515?lang=en_us&edition=fundamental","pubTime":"2025-12-18 09:01","pubTimestamp":1766019665,"startTime":"0","endTime":"0","summary":"InMed Pharmaceuticals Inc. held its annual general and special meeting of shareholders on December 17, 2025. Shareholders approved the election of the board of directors and the appointment of CBIZ CPAs P.C. as auditors for the following year. Approval was also granted for the potential issuance of 20% or more of the company's common shares pursuant to the Standby Equity Purchase Agreement with YA II PN, Ltd.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. InMed Pharmaceuticals Inc. published the original content used to generate this news brief via Newsfile  on December 18, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251218:nNDL9J0pkw:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","INM"],"gpt_icon":0},{"id":"2591647203","title":"ADVISORY-Dated alerts on InMed Pharmaceuticals withdrawn","url":"https://stock-news.laohu8.com/highlight/detail?id=2591647203","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591647203?lang=en_us&edition=fundamental","pubTime":"2025-12-15 23:05","pubTimestamp":1765811124,"startTime":"0","endTime":"0","summary":"ADVISORY-Dated alerts on InMed Pharmaceuticals withdrawnAlerts published on InMed Pharmaceuticals INM.O expecting the H.R. 5371 Act to have a negative impact on its unit Baymedica were dated and have ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251215:nFWN3XL0AQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","INM"],"gpt_icon":0},{"id":"2591480642","title":"InMed Pharmaceuticals Inc - Expects Negative Impact on Baymedica From New Act H.r. 5371 - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2591480642","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591480642?lang=en_us&edition=fundamental","pubTime":"2025-12-15 22:37","pubTimestamp":1765809436,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251215:nFWN3XL0AQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["INM","BK4007"],"gpt_icon":0},{"id":"2591642942","title":"BayMedica Faces Uncertainty as New Law Threatens Commercial Operations","url":"https://stock-news.laohu8.com/highlight/detail?id=2591642942","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591642942?lang=en_us&edition=fundamental","pubTime":"2025-12-15 22:33","pubTimestamp":1765809187,"startTime":"0","endTime":"0","summary":"BayMedica, InMed Pharmaceuticals Subsidiary, Faces Material Impact from New Legislation. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. InMed Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 15, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251215:nNDL1VyMW8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INM","BK4007"],"gpt_icon":0},{"id":"2584814511","title":"Why Did Vivakor Shares Surge 17% After Hours?","url":"https://stock-news.laohu8.com/highlight/detail?id=2584814511","media":"Benzinga_recent_news","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584814511?lang=en_us&edition=fundamental","pubTime":"2025-11-20 16:55","pubTimestamp":1763628900,"startTime":"0","endTime":"0","summary":"Vivakor shares jumped 17% in after-hours trading after the company reported widening losses and rising interest expenses.","market":"sh","thumbnail":"https://cdn.benzinga.com/files/images/story/2025/11/20/Market-Prudence-To-Increase-Amid-Growing.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2025/11/20/Market-Prudence-To-Increase-Amid-Growing.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/markets/equities/25/11/48969121/why-did-vivakor-shares-surge-17-after-hours","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/markets/equities/25/11/48969121/why-did-vivakor-shares-surge-17-after-hours","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["VIVK","BK4007","INM","BK4120","BK4144"],"gpt_icon":0},{"id":"2584183421","title":"What's Driving InMed's (INM) 22% After-Hours Surge?","url":"https://stock-news.laohu8.com/highlight/detail?id=2584183421","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584183421?lang=en_us&edition=fundamental","pubTime":"2025-11-20 15:28","pubTimestamp":1763623737,"startTime":"0","endTime":"0","summary":"InMed shares jumped 22% in after-hours trading after the company reported encouraging large-animal study results for its Alzheimer&#39;s drug candidate INM-901.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/markets/equities/25/11/48968515/whats-driving-inmeds-inm-22-after-hours-surge","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","GLP","BK4590","BK4144","INM"],"gpt_icon":0},{"id":"2584979338","title":"InMed Pharmaceuticals Completes Key Study for INM-901","url":"https://stock-news.laohu8.com/highlight/detail?id=2584979338","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584979338?lang=en_us&edition=fundamental","pubTime":"2025-11-20 05:51","pubTimestamp":1763589103,"startTime":"0","endTime":"0","summary":"InMed Pharmaceuticals ( ($INM) ) just unveiled an announcement. On November 18, 2025, InMed Pharmaceuticals announced the successful completion of ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/inmed-pharmaceuticals-completes-key-study-for-inm-901?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/inmed-pharmaceuticals-completes-key-study-for-inm-901?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["INM","BK4007"],"gpt_icon":0},{"id":"2584893095","title":"InMed Completes Key Pharmacokinetic Studies for Alzheimer’s Candidate INM-901","url":"https://stock-news.laohu8.com/highlight/detail?id=2584893095","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584893095?lang=en_us&edition=fundamental","pubTime":"2025-11-18 21:14","pubTimestamp":1763471651,"startTime":"0","endTime":"0","summary":"InMed Pharmaceuticals ( ($INM) ) has provided an update. InMed Pharmaceuticals announced the successful completion of pharmacokinetic studies for i...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/inmed-completes-key-pharmacokinetic-studies-for-alzheimers-candidate-inm-901?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/inmed-completes-key-pharmacokinetic-studies-for-alzheimers-candidate-inm-901?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","INM"],"gpt_icon":0},{"id":"2584932967","title":"InMed Pharmaceuticals Completes Large Animal Study for Alzheimer's Drug Candidate INM-901","url":"https://stock-news.laohu8.com/highlight/detail?id=2584932967","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584932967?lang=en_us&edition=fundamental","pubTime":"2025-11-18 20:31","pubTimestamp":1763469066,"startTime":"0","endTime":"0","summary":"InMed Pharmaceuticals Inc. announced the successful completion of pharmacokinetic studies in large animal models for its Alzheimer's disease candidate, INM-901. The company reported that the oral formulation of INM-901 demonstrated a favorable bioavailability profile and achieved anticipated therapeutic levels of systemic exposure over a seven-day dosing period. Neurological assessments found no adverse neural or behavioral effects. These results, which have already been obtained, will support the design and planning of first-in-human clinical trials. InMed is preparing for a pre-IND meeting with the FDA and advancing further studies to support an IND submission.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. InMed Pharmaceuticals Inc.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251118:nNDL2hFfTp:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INM","BK4007"],"gpt_icon":0},{"id":"2581445045","title":"InMed Pharmaceuticals reports $1.1 million in BayMedica revenues for Q1 fiscal 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2581445045","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581445045?lang=en_us&edition=fundamental","pubTime":"2025-11-07 05:51","pubTimestamp":1762465916,"startTime":"0","endTime":"0","summary":"InMed Pharmaceuticals Inc. reported cash and cash equivalents of $9.3 million as of September 30, 2025, down from $11.1 million at the end of June 2025. Short-term investments were $42.9 thousand, and accounts receivable totaled $343.5 thousand. Inventories stood at $890.8 thousand. General and administrative expenses were $1.5 million for the three months ended September 30, 2025, and are expected to remain stable for the remainder of fiscal 2026. Research and development expenses decreased due to reduced spending on external contractors and compensation but are anticipated to increase as preclinical and IND-enabling work on lead program INM-901 advances. The company expects available cash to fund planned operations into the fourth quarter of calendar year 2026. Business developments include progress toward clinical readiness for INM-901, a small-molecule therapy targeting multiple pathways associated with Alzheimer's disease, and the addition of two new directors to the board.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nNDL9qKrrK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","INM"],"gpt_icon":0},{"id":"2578652899","title":"InMed Pharmaceuticals Inc. Announces Date for Upcoming Shareholder Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2578652899","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578652899?lang=en_us&edition=fundamental","pubTime":"2025-10-25 04:55","pubTimestamp":1761339326,"startTime":"0","endTime":"0","summary":"InMed Pharmaceuticals Inc. has announced that it will hold its annual general and special meeting of shareholders virtually on December 17, 2025. Shareholders will have the opportunity to vote on key matters relating to the company. The management information circular with detailed information about the meeting and the matters to be addressed is available on the company's website, as well as through regulatory filings.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. InMed Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on October 24, 2025, and is solely responsible for th","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251024:nNDL8pR5Ng:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INM","BK4007"],"gpt_icon":0},{"id":"2578547730","title":"InMed Pharmaceuticals Files Amendment to Annual Report","url":"https://stock-news.laohu8.com/highlight/detail?id=2578547730","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578547730?lang=en_us&edition=fundamental","pubTime":"2025-10-25 04:06","pubTimestamp":1761336368,"startTime":"0","endTime":"0","summary":"InMed Pharmaceuticals Inc. has filed an amendment to its annual report on Form 10-K/A for the fiscal year ended June 30, 2025. The amendment includes information previously omitted from the original filing, specifically Items 10, 11, 12, 13, and 14 of Part III of Form 10-K, as the company will not file a definitive proxy statement within the required timeframe. Additionally, new certifications from the principal executive officer and principal financial officer have been filed as exhibits. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. InMed Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251024:nNDL94bp2w:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INM","BK4007"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.inmedpharma.com","stockEarnings":[{"period":"1week","weight":-0.0272},{"period":"1month","weight":-0.0176},{"period":"3month","weight":-0.3448},{"period":"6month","weight":-0.6349},{"period":"1year","weight":-0.6945},{"period":"ytd","weight":-0.1872}],"compareEarnings":[{"period":"1week","weight":-0.0136},{"period":"1month","weight":-0.0187},{"period":"3month","weight":-0.0145},{"period":"6month","weight":0.0149},{"period":"1year","weight":0.1887},{"period":"ytd","weight":-0.0189}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, develops a pipeline of prescription-based products. The company operates through two segments, the InMed and the BayMedica. The InMed segment researches and develops cannabinoid-based pharmaceuticals products. The BayMedica segment develops proprietary manufacturing technologies to produce and sell rare cannabinoids for the health and wellness industry. The company's prescription-based products include rare cannabinoids and novel cannabinoid analogs for the treatment of diseases with high unmet medical needs. Its lead product is INM-755, a cannabinol topical skin cream, which is in Phase 2 clinical trial for the treatment of epidermolysis bullosa. The company is also developing INM-088, which is in preclinical studies for the treatment of glaucoma; INM-405 for the treatment of pain; and cannabinoid-based treatments for various diseases, including dermatology and ocular diseases. In addition, it offers IntegraSyn, an integrated biosynthesis-based manufacturing approach, for pharmaceutical-grade cannabinoids; and cannabichromene, cannabicitran, cannabidivarin, and tetrahydrocannabivarin. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is headquartered in Vancouver, Canada.","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":-0.055524},{"month":2,"riseRate":0.333333,"avgChangeRate":-0.102625},{"month":3,"riseRate":0.333333,"avgChangeRate":-0.135102},{"month":4,"riseRate":0.6,"avgChangeRate":0.072322},{"month":5,"riseRate":0.4,"avgChangeRate":-0.055462},{"month":6,"riseRate":0.4,"avgChangeRate":-0.082897},{"month":7,"riseRate":0.2,"avgChangeRate":-0.134974},{"month":8,"riseRate":0.2,"avgChangeRate":0.013552},{"month":9,"riseRate":0.2,"avgChangeRate":-0.118637},{"month":10,"riseRate":0.2,"avgChangeRate":-0.198876},{"month":11,"riseRate":0.2,"avgChangeRate":-0.092328},{"month":12,"riseRate":0.166667,"avgChangeRate":-0.132014}],"exchange":"NASDAQ","name":"InMed Pharmaceuticals Inc","nameEN":"InMed Pharmaceuticals Inc"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"InMed Pharmaceuticals Inc(INM),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest InMed Pharmaceuticals Inc(INM) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"InMed Pharmaceuticals Inc,INM,InMed Pharmaceuticals Inc股票,InMed Pharmaceuticals Inc股票老虎,InMed Pharmaceuticals Inc股票老虎国际,InMed Pharmaceuticals Inc行情,InMed Pharmaceuticals Inc股票行情,InMed Pharmaceuticals Inc股价,InMed Pharmaceuticals Inc股市,InMed Pharmaceuticals Inc股票价格,InMed Pharmaceuticals Inc股票交易,InMed Pharmaceuticals Inc股票购买,InMed Pharmaceuticals Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"InMed Pharmaceuticals Inc(INM),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest InMed Pharmaceuticals Inc(INM) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}